Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890124 | 0.91 | MAPK14 (1.00) | MAPK14PTGS2 | |
| SCHEMBL6280887 | 0.87 | MAPK14 (1.00) | MAPK14PTGS2 | |
| SCHEMBL27482773 | 0.87 | MAPK14 (0.63) | MAPK14PTGS2 | |
| SCHEMBL3901408 | 0.86 | MAPK14 (0.77) | MAPK14PTGS2 | |
| SCHEMBL4265446 | 0.85 | MAPK14 (0.75) | MAPK14PTGS2 | |
| SCHEMBL4258899 | 0.85 | MAPK14 (0.75) | MAPK14PTGS2 | |
| SCHEMBL31139616 | 0.84 | MAPK14 (0.86) | MAPK14PTGS2 | |
| SCHEMBL4259023 | 0.84 | MAPK14 (0.86) | MAPK14PTGS2 | |
| SCHEMBL3886817 | 0.84 | MAPK14 (0.81) | MAPK14PTGS2 | |
| SCHEMBL3898491 | 0.84 | MAPK14 (0.73) | MAPK14PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495018-B2 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-24 | — | — | US | claimed |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | claimed |
| US-7495018-B2 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20090048307-A1 | 5-pyridyl-1, 3-azole compounds, process for producing the same and use there of | OHKAWA SHIGENORI | 2009-02-19 | — | — | US | disclosed |
| US-7276527-B2 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-02 | — | — | US | disclosed |
| US-7199124-B2 | JNK inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1180518-B1 | 5-PYRIDYL-1,3-AZOLE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-7101899-B1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-05 | — | — | US | disclosed |
| US-20060135566-A1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | OHKAWA SHIGENORI | 2006-06-22 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040063946-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1364949-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1268474-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1180518-A1 | 5-PYRIDYL-1,3-AZOLE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | disclosed |
| WO-2001074811-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | MAPK14 50/4885PTGS2 57/4885 |
| US-20060135566-A1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | ADORA3, MAPK4, MAPK3 | MAPK14 47/4885PTGS2 699/4885 |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | MAPK1, MAP4K2, MAPK4 | MAPK14 31/4885PTGS2 766/4885 |
| US-20090048307-A1 | 5-pyridyl-1, 3-azole compounds, process for producing the same and use there of | ADORA3, ADORA1, MAPK3 | MAPK14 73/4885PTGS2 728/4885 |
| US-20040063946-A1 | Jnk inhibitor | MAPK1, MAPK7, MAP3K7 | MAPK14 14/4885PTGS2 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.